NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, version 1.2020 Guidelines


Authors: Daly, M. B.; Pilarski, R.; Yurgelun, M. B.; Berry, M. P.; Buys, S. S.; Dickson, P.; Domchek, S. M.; Elkhanany, A.; Friedman, S.; Garber, J. E.; Goggins, M.; Hutton, M. L.; Khan, S.; Klein, C.; Kohlmann, W.; Kurian, A. W.; Laronga, C.; Litton, J. K.; Mak, J. S.; Menendez, C. S.; Merajver, S. D.; Norquist, B. S.; Offit, K.; Pal, T.; Pederson, H. J.; Reiser, G.; Shannon, K. M.; Visvanathan, K.; Weitzel, J. N.; Wick, M. J.; Wisinski, K. B.; Dwyer, M. A.; Darlow, S. D.
Title: NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, version 1.2020
Abstract: The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2, pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 18
Issue: 4
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2020-04-01
Start Page: 380
End Page: 391
Language: English
DOI: 10.6004/jnccn.2020.0017
PUBMED: 32259785
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 May 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Kenneth Offit
    788 Offit